Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CAP-1002
CAPRICOR THERAPEUTICS, INC.
Covid19
1 trial -
CAP-1002
CAPRICOR THERAPEUTICS, INC.
Muscular Dystrophies
1 trial -
CAP-1002 Allogeneic Cardiosphere-Derived Cells
CAPRICOR THERAPEUTICS, INC.
Myocardial Infarction
1 trial -
CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,
GlaxoSmithKline
MMRp/ MSS colon cancer
1 trial -
CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB
Ningbo Cancer Hospital
Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.
1 trial -
CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID
Ningbo Cancer Hospital
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication
1 trial -
CAR T-cell therapy
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia With Failed Remission
1 trial -
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
Daihong Liu
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
1 trial -
CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
1 trial -
CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
advanced ALK-positive non-small cell lung cancer
1 trial -
CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy
Tour Hekla
Pneumocystis pneumonia
1 trial -
CBP-201
S.L
Moderate-to-severe Atopic Dermatitis
2 trials -
CBP-201
S.L
Moderate to Severe Persistent Asthma
1 trial -
CEFEPIME , AMIKACIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR
Pari Pharma GmbH
gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation
1 trial -
CERC-002
Avalo Therapeutics
COVID-19 Pneumonia
1 trial -
CERC-301
Avalo Therapeutics
Major Depressive Disorder
2 trials -
CERE-110: Adeno-Associated Virus injection Surgery
SANGAMO THERAPEUTICS, INC
Alzheimer's Disease
1 trial -
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
SANGAMO THERAPEUTICS, INC
Idiopathic Parkinson's Disease
1 trial -
CERE-120: Adeno-Associated Virus Delivery of Neurturin
SANGAMO THERAPEUTICS, INC
Idiopathic Parkinson's Disease
1 trial -
CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Chiesi Farmaceutici S.p.A
Mild to moderate asthma
1 trial -
CHOP+selinexor+5-Azacitidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T Cell Lymphoma
1 trial -
CINRYZE with rHuPH20
HALOZYME THERAPEUTICS, INC.
Hereditary Angioedema
1 trial -
CLBS03 Low Dose
LISATA THERAPEUTICS, INC.
Diabetes Mellitus
1 trial -
CLBS12
LISATA THERAPEUTICS, INC.
Critical Limb Ischemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources